Summary
Gastric Cancer (GC) is the fifth most common malignancy in the world. Being the third leading cause of death, it claimed 723,000 lives worldwide in 2012, 12 lives/day in the UK (2014-2016), 29 lives/day in U.S. in 2018 and 6th most common in Europe. With such high number of deaths, it can be compared to no less than an epidemic disease. According to International Agency for Research on Cancer, 89% of all GC cases are attributed to infection from Helicobacter Pylori (Hp). H. pylori produces an enzyme called urease which causes creation of an alkaline buffer zone which keeps it safe from gastric acid and silences the immune system of stomach against this microbe. This result in formation of gastric ulcer which grows into cancerous tumour. Early diagnosis of H. pylori is important for understanding pathology of gastric cancer and starting early therapy. But high cost, ambiguous diagnosis and poor patient engagement of existing diagnostic methods leads to late/advanced stage diagnosis of cancer. Patients spend $700-$1800 for standard 2 week triple drug therapy. Such high cost in low and middle income country (LMIC) is a burden where 33 million individual face catastrophic health expense & cancer take their toll at the cost of human life. This cost can further increase with late diagnosis. H. Pylori-Scopy aims to reduce the cost by performing early diagnosis with single stop, easily accessible, portable, unambiguous, instantaneous screening device, which results in increased patient engagement with no waiting for medical reports and quick medication. H. Pylori-Scopy is a combination of light based Raman/Fourier Transform Infrared, & Chitosan-Magnetic-Swob spectroscopy, which offer an unambiguous addendum tool for h-pylori diagnosis using standard endoscopy, suitable not only for in-theatre but also for portable/accessible use in the LMIC regions. H.Pylori-Scopy integrates all three techniques into an endoscopic device which will work with low-cost robotic control.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/844696 |
| Start date: | 02-09-2019 |
| End date: | 01-09-2021 |
| Total budget - Public funding: | 224 933,76 Euro - 224 933,00 Euro |
Cordis data
Original description
Gastric Cancer (GC) is the fifth most common malignancy in the world. Being the third leading cause of death, it claimed 723,000 lives worldwide in 2012, 12 lives/day in the UK (2014-2016), 29 lives/day in U.S. in 2018 and 6th most common in Europe. With such high number of deaths, it can be compared to no less than an epidemic disease. According to International Agency for Research on Cancer, 89% of all GC cases are attributed to infection from Helicobacter Pylori (Hp). H. pylori produces an enzyme called urease which causes creation of an alkaline buffer zone which keeps it safe from gastric acid and silences the immune system of stomach against this microbe. This result in formation of gastric ulcer which grows into cancerous tumour. Early diagnosis of H. pylori is important for understanding pathology of gastric cancer and starting early therapy. But high cost, ambiguous diagnosis and poor patient engagement of existing diagnostic methods leads to late/advanced stage diagnosis of cancer. Patients spend $700-$1800 for standard 2 week triple drug therapy. Such high cost in low and middle income country (LMIC) is a burden where 33 million individual face catastrophic health expense & cancer take their toll at the cost of human life. This cost can further increase with late diagnosis. H. Pylori-Scopy aims to reduce the cost by performing early diagnosis with single stop, easily accessible, portable, unambiguous, instantaneous screening device, which results in increased patient engagement with no waiting for medical reports and quick medication. H. Pylori-Scopy is a combination of light based Raman/Fourier Transform Infrared, & Chitosan-Magnetic-Swob spectroscopy, which offer an unambiguous addendum tool for h-pylori diagnosis using standard endoscopy, suitable not only for in-theatre but also for portable/accessible use in the LMIC regions. H.Pylori-Scopy integrates all three techniques into an endoscopic device which will work with low-cost robotic control.Status
CLOSEDCall topic
MSCA-IF-2018Update Date
28-04-2024
Images
No images available.
Geographical location(s)
